Ibnsina Pharma (CAI:ISPH) Long-Term Debt: E£1,243 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:ISPH Ibnsina Pharma CAI:ISPH
86 GF Score
Price E£13.60
GF Value E£10.76
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Ibnsina Pharma Long-Term Debt?

Ibnsina Pharma CAI:ISPH 86 Long-Term Debt is E£1,243 Mil as of Mar. 2026. GuruFocus rates CAI:ISPH with a GF Score™ of 86/100 and a GF Value™ of E£10.76 (Modestly Overvalued). The stock has 10 warning signs investors should review.

Ibnsina Pharma's Long-Term Debt for the quarter that ended in Mar. 2026 was E£1,243 Mil.

Ibnsina Pharma's quarterly Long-Term Debt increased from Sep. 2025 (E£86 Mil) to Dec. 2025 (E£891 Mil) and increased from Dec. 2025 (E£891 Mil) to Mar. 2026 (E£1,243 Mil).

Ibnsina Pharma's annual Long-Term Debt declined from Dec. 2023 (E£556 Mil) to Dec. 2024 (E£47 Mil) but then increased from Dec. 2024 (E£47 Mil) to Dec. 2025 (E£891 Mil).

Ibnsina Pharma  (CAI:ISPH) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Ibnsina Pharma Long-Term Debt Related Terms

Ibnsina Pharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Ibnsina Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ibnsina Pharma Long-Term Debt Chart

Ibnsina Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 852.18 556.02 47.46 891.23

Ibnsina Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.60 74.91 86.16 891.23 1,242.68
CAI:ISPH
86GF Score
Ibnsina Pharma CAI:ISPH
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of E£1,243 Mil mean?
Ibnsina Pharma (CAI:ISPH) has a Long-Term Debt of E£1,243 Mil as of Mar. 2026.
Is Ibnsina Pharma's Long-Term Debt too high?
Ibnsina Pharma's current Long-Term Debt is E£1,243 Mil. Overall, Ibnsina Pharma has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Long-Term Debt compare to MCK and COR?
Ibnsina Pharma's Long-Term Debt of E£1,243 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Distribution company?
A good Long-Term Debt depends on the Medical Distribution industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Ibnsina Pharma's current Long-Term Debt is E£1,243 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.76, compared to a current price of E£13.60 — trading 26.4% above its estimated fair value. The current Long-Term Debt is E£1,243 Mil. Ibnsina Pharma's overall GF Score™ is 86/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Long-Term Debt is E£1,243 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?

Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued. The current stock price of E£13.60 is trading 26.4% above its estimated GF Value™ of E£10.76. GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.

Key valuation signals for CAI:ISPH:

  • Long-Term Debt: E£1,243 Mil
  • GF Value™: E£10.76 vs. price of E£13.60 (26.4% above fair value)
  • GF Score™: 86/100 with 10 warning signs

No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ibnsina Pharma Business Description

Address Industrial zone 1, PO box 91, Obour, EGY
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
86GF Score

Get the complete analysis for CAI:ISPH

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£13.60
Price
E£10.76
GF Value